Stock AnalizBridgeBio Pharma, Inc. BBIO
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
BridgeBio Pharma, Inc. (BBIO) is a healthcare company listed in the US with a market value of about $15.3B. In the twelve months to September 30, 2026 it had revenue of $946M and net income of -$592M, a net margin of -62.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 127% a year.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $946M | $502M | $222M | $9M | $78M | $70M | $8M | $41M | — | — |
| Net income | -$592M | -$725M | -$536M | -$643M | -$481M | -$563M | -$449M | -$261M | -$131M | -$31M |
| Free cash flow | -$370M | -$447M | -$522M | -$529M | -$424M | -$511M | -$407M | -$256M | -$139M | -$41M |
| EPS (diluted) | $-3.03 | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | $-2.48 | $-2.12 | $-1.00 |
| Net margin | -62.6% | -144.4% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.5% | — | — |
| ROIC | — | — | — | — | — | — | -220.2% | -41.1% | -39.3% | -40.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 20 analysts is $106.85, 36% above the current price; targets range from $80.00 to $156.00; the consensus rating is “Strong buy”; expected EPS is $-2.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does BridgeBio Pharma pay a dividend?
Not currently.
Is BridgeBio Pharma a good stock to buy?
We do not give buy or sell advice. BridgeBio Pharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.